KalVista Pharmaceuticals Inc. (KALV) is all set to be acquired by Chiesi Group, an international research-focused biopharmaceutical group, for $27.00 per share in cash, representing an equity consideration of roughly $1.9 billion.
The flagship drug of KalVista is EKTERLY, the first and only oral on-demand treatment for Hereditary Angioedema (HAE). The US commercial launch of EKTERLY was initiated on July 7, 2025. The drug generated net product revenue of $49.1 million in 2025.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com